These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33130696)

  • 21. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
    Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
    Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of Treatment Safety Between Brand-Name Product and Biosimilar of Trastuzumab].
    Tatsuta R; Sumimoto T; Nakahara R; Tanaka R; Itoh H
    Gan To Kagaku Ryoho; 2021 Jul; 48(7):945-949. PubMed ID: 34267033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars.
    Peliçário Vargas B; Sari MHM; Ferreira LM
    Anticancer Agents Med Chem; 2022; 22(14):2507-2516. PubMed ID: 35236272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study.
    Saito Y; Tamaki S; Hasegawa H; Takahashi K; Tokutome A; Takekuma Y; Yamashita H; Komatsu Y; Sugawara M
    Biol Pharm Bull; 2021; 44(4):474-477. PubMed ID: 33790098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar.
    Paek K; Kim GW; Ahn SY; Lim JH; Jung D; Kim S; Lee JH
    BioDrugs; 2019 Dec; 33(6):661-671. PubMed ID: 31549311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
    Pegram MD; Bondarenko I; Zorzetto MMC; Hingmire S; Iwase H; Krivorotko PV; Lee KS; Li RK; Pikiel J; Aggarwal R; Ewesuedo R; Freyman A; Li R; Vana A; Yin D; Zacharchuk C; Tan-Chiu E
    Br J Cancer; 2019 Jan; 120(2):172-182. PubMed ID: 30568294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
    Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
    Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
    Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
    BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of the trastuzumab biosimilar CT-P6.
    Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluating imbalances of adverse events during biosimilar development.
    Vana AM; Freyman AW; Reich SD; Yin D; Li R; Anderson S; Jacobs IA; Zacharchuk CM; Ewesuedo R
    MAbs; 2016 Jul; 8(5):861-6. PubMed ID: 27050730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab biosimilar shows potential for breast cancer.
    Baker H
    Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
    [No Abstract]   [Full Text] [Related]  

  • 35. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab.
    Jassem S; Wang W; Sweet H; Manoukian R; Chow V; Kanakaraj P; Hutterer KM; Kuhns S; Foltz IN; Chen Q; Ferbas J; McBride HJ
    Pharm Res; 2019 Nov; 36(12):177. PubMed ID: 31696314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital.
    Mendes D; Abrantes J; Rigueiro G; Pais AF; Penedones A; Alves C; Batel-Marques F
    J Oncol Pharm Pract; 2021 Sep; 27(6):1432-1438. PubMed ID: 32936721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
    Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
    Oh SY; Lee S; Huh SJ; Lee J; Kim ST; Park SH; Lim HY; Kang WK; Kang BW; Kim JG; Lee HJ; Kim JH; Kang JH; Kim H
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):501-508. PubMed ID: 30535535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.